Vanguard Group
JSPR icon

Vanguard Group’s Jasper Therapeutics JSPR Stock Holding History

Vanguard Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.43M Buy
1,326,512
+293,670
+28% +$590K ﹤0.01% 3499
2025
Q3 		$2.46M Buy
1,032,842
+408,245
+65% +$1.24M ﹤0.01% 3512
2025
Q2 		$3.47M Sell
624,597
-54,855
-8% -$270K ﹤0.01% 3333
2025
Q1 		$2.92M Sell
679,452
-30,032
-4% -$200K ﹤0.01% 3358
2024
Q4 		$15.2M Buy
709,484
+15,059
+2% +$313K ﹤0.01% 2730
2024
Q3 		$13.1M Buy
694,425
+4,366
+0.6% +$86.9K ﹤0.01% 2820
2024
Q2 		$15.7M Buy
690,059
+77,314
+13% +$1.85M ﹤0.01% 2689
2024
Q1 		$18M Buy
612,745
+203,449
+50% +$3.61M ﹤0.01% 2655
2023
Q4 		$3.23M Buy
409,296
+30,000
+8% +$201K ﹤0.01% 3436
2023
Q3 		$2.66M Buy
379,296
+10,460
+3% +$128K ﹤0.01% 3491
2023
Q2 		$5.05M Sell
368,836
-3,779
-1% -$56.1K ﹤0.01% 3293
2023
Q1 		$6.74M Buy
372,615
+319,571
+602% +$5.91M ﹤0.01% 3163
2022
Q4 		$256K Buy
53,044
+32
+0.1% +$214 ﹤0.01% 4254
2022
Q3 		$418K Buy
53,012
+4,956
+10% +$90.7K ﹤0.01% 4263
2022
Q2 		$928K Buy
48,056
+274
+0.6% +$7.8K ﹤0.01% 4112
2022
Q1 		$1.7M Sell
47,782
-568
-1% -$25.6K ﹤0.01% 4023
2021
Q4 		$3.79M Buy
+48,350
New +$4.52M ﹤0.01% 3766

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group's JSPR Position: Q4 2025 in Review

Vanguard Group increased its Jasper Therapeutics (JSPR) stake by 28% in Q4 2025, buying an estimated $590K and bringing the position to 1,326,512 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3499.

Vanguard Group first reported a position in JSPR in Q4 2021 and has held it in 17 quarters since. The position peaked at $18M in Q1 2024. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Vanguard Group held 1,326,512 shares of Jasper Therapeutics worth $2.43M as of Q4 2025.
  • Vanguard Group bought 293,670 Jasper Therapeutics shares in Q4 2025, an estimated $590K.
  • Jasper Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3499 holding.
  • Vanguard Group first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Jasper Therapeutics position peaked at $18M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.